XML 20 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Income - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]      
Product revenues $ 1,046,150 $ 913,098 $ 971,684
Type of Revenue [Extensible List] us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember
Cost of sales $ 742,519 $ 644,994 $ 683,349
Gross margin 303,631 268,104 288,335
Operating expenses:      
Research and development expenses 91,807 81,968 91,033
Reimbursed research and development expenses (16,593) (13,928) (18,557)
Net research and development expenses 75,214 68,040 72,476
Selling, general and administrative expenses 109,554 105,044 118,680
Restructuring expenses 3,857 5,803 12,919
Total operating expenses 188,625 178,887 204,075
Operating income 115,006 89,217 84,260
Interest expense, net (2,758) (4,559) (4,763)
Foreign currency gain (loss) 1,487 (5,439) 2,326
Impairment loss     (21,206)
Net loss on divestitures     (1,587)
Other income 117 2,337 121
Earnings before income tax 113,852 81,556 59,151
Income tax expense 20,418 21,866 10,285
Net income $ 93,434 $ 59,690 $ 48,866
Basic earnings per share $ 2.82 $ 1.83 $ 1.48
Diluted earnings per share $ 2.79 $ 1.81 $ 1.47
Weighted average number of shares – basic 33,085,732 32,666,025 33,120,076
Weighted average number of shares – diluted 33,509,720 33,028,104 33,297,589